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a  b  s  t  r  a  c  t
The  study  of  gene  expression  has  undergone  a  transformation  in  the  past decade  as  the beneﬁts  of the
sequencing  of  the  human  genome  have  made  themselves  felt.  Increasingly,  genome  wide approaches
are  being  applied  to  the  analysis  of  gene  expression  in human  disease  as  a route  to understanding  the
underlying  pathogenic  mechanisms.  In  this  review,  we  will summarise  current  state  of gene  expression
studies  of the  brain  in Parkinson’s  disease,  and  examine  how  these  techniques  can  be  used  to gain  aneywords:
arkinson’s disease
icroarray
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insight  into  aetiology  of  this  devastating  disorder.
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. Background
Parkinson’s disease (PD) is a neurodegenerative movement dis-
neurotransmitter, and of the deposition of protein within the brain
as intracellular inclusions called Lewy bodies [68].
Over the past ﬁfteen years, an increasingly detailed knowledge
rder characterised by resting tremor, bradykinesia, stiffness of
ovement and postural instability. These movement problems
re largely a consequence of substantial cell loss in the Substan-
ia nigra pars compacta and concomitant loss of dopamine (DA)
∗ Corresponding authors. Tel.: +44 020 3448 4016; fax: +44 020 7278 5069.
E-mail addresses: patrick.lewis@ucl.ac.uk (P.A. Lewis),
ookson@mail.nih.gov (M.R. Cookson).
361-9230     © 2011 Elsevier Inc.  
oi:10.1016/j.brainresbull.2011.11.016
Open access under CC BY license.of the genetic factors that contribute to PD has emerged [49]. There
are now a number of identiﬁed PARK loci that are linked to autoso-
mal  dominant or recessive forms of disease. Furthermore, in the last
24 months several genome wide association studies have opened
the door to a wider understanding of genes involved in the sporadic
form of the disease [46,49,96,98,104,110].  Despite these advances,
the mechanisms underlying cellular degeneration in the brains of
people with PD remain poorly understood.
The development of genome wide approaches for analysing
gene expression may  yield insights into the underlying
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echanisms causing PD. By examining the expression of genes
ithin the brains of people with disease post mortem, and compar-
ng these data to controls without PD, it is hoped that expression
ignatures for disease can be identiﬁed [90]. This, in turn, could
ighlight pathways that lead to dysfunction – an approach that has
ielded important advances in other disorders [128]. In this review,
he importance of gene expression in PD will be examined using
he -synuclein gene and MPTP toxicity as pathﬁnders for the
ore complex analyses facilitated by whole genome analysis. The
urrent status of such studies using brain samples from patients
ill then be summarised and discussed with a view to the future
irections that may  be helpful to expand this work.
. SNCA and MAPT expression in Parkinson’s disease
That gene expression is a crucial component of the disease
rocess in Parkinson’s can be illustrated using the example of -
ynuclein. This gene was ﬁrst linked to PD with the identiﬁcation
f an A53T mutation in SNCA (the gene that encodes the -synuclein
rotein) as the causative insult in a large family of Mediterranean
rigin with autosomal dominant inherited Parkinson’s disease [92].
oon after this, -synuclein was identiﬁed as a major component
f Lewy bodies, suggesting that the same protein is also linked to
poradic PD [111].
A key discovery that supports the role of wild type -synuclein
n inherited and sporadic PD was the identiﬁcation of a tripli-
ation of the SNCA locus, resulting in a doubling of -synuclein
xpression, in a family with inherited parkinsonism and dementia
78,107]. Subsequently, several additional families were reported
here duplications or triplications of the -synuclein gene were
ound [16]. Intriguingly, there appeared to be a correlation between
he gene dosage and the severity of disease [39,57]. These studies
rovided substantive evidence that large increases in the expres-
ion of -synuclein can result in neurodegeneration, and that the
mount of expression is negatively correlated with age at onset and
ositively correlated with disease severity.
Further evidence that there may  be a connection between the
evel of -synuclein expression and risk for development of PD out-
ide of rare families has recently been provided by genome wide
ssociation studies. Common genetic variation at the SNCA locus
as been identiﬁed as one of the most consistent genetic risk fac-
ors for PD [46,98,104,110]. This suggests a model where the level of
-synuclein expression level in an individual’s brain is a signiﬁcant
eterminant of risk for neuronal degeneration.
Another important gene for PD is MAPT, which encodes the
icrotubule associated protein tau. Deposition of Tau is seen in
lzheimer’s disease as tangles, but is not generally seen in PD [129].
espite this, the MAPT locus has been identiﬁed as a major risk fac-
or for PD in several genome wide association studies. Using data
rom human brain, it has been shown that the risk alleles for PD
re associated with higher levels of expression of MAPT than pro-
ective alleles [104]. Therefore, like SNCA, too much MAPT increases
he risk for PD.
SNCA and MAPT are important examples of the link between the
xpression of individual genes and PD that has been elucidated by
he interaction of clinical medicine, genetics and neuropathology.
owever, it remains likely that there will be additional inﬂuences
n pathogenesis that might be rather subtle and may  not be mea-
urable at the level of DNA. Using genome wide expression analysis
pproaches may  allow a broader and much more rapid approach to
dentifying additional genes, families of genes and pathways that
re linked to neurodegeneration in Parkinson’s. In the following
ections we will identify several linked questions related to the
athophysiology of PD and discuss where gene expression proﬁling
ay  be able to add some novel insights.rch Bulletin 88 (2012) 302– 312 303
3.  Gene expression, regional development and vulnerability
Gene expression may  be a clue to the solution of one of the
major unanswered questions in the study of PD, and indeed in neu-
rodegeneration as a whole: the regional preferential vulnerability
exhibited by neurons within the brain. In PD, a substantial pro-
portion of neuronal death, but not all, is localised to dopaminergic
neurons in the Substantia nigra [11,27,35].  Surveys of the pathology
in PD suggest that there are distinct patterns in the spread of cell
loss and Lewy body burden [12,27].
The reasons for this pattern of degeneration are unknown but
can be hypothesised that underlying variability in gene expres-
sion across the brain that speciﬁes cellular phenotypes and roles
is important [13,77].  Precisely how gene expression, regional and
cellular identity map  on to patterns of neurodegeneration is a
matter of debate [28,102,114]. One example of a link between
speciﬁc gene expression and neurodegeneration is given by neu-
rotoxicity linked to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP). This chemical ﬁrst came to light in reports of intravenous
drug users exposed to MPTP who developed a parkinsonian syn-
drome [66,67].  Subsequent investigations demonstrated that the
reason for this toxicity was due to conversion of MPTP to a toxic
cation, 1-methyl-4-phenylpyridinium (MPP+) by monoamineoxi-
dase B in glial cells within the brain, and the selective uptake of
this toxin by the dopamine transporter by doperminergic neurons
[18,19,59,120]. This is a clear example of how a speciﬁc combina-
tion of gene expression in the presence of an acute environmental
insult can lead to a deﬁnite pattern of neurodegeneration. The
principle of regional gene expression and patterns of neurodegen-
eration, however, is one that can be extended and explored in much
greater detail using genome wide expression studies.
4. General aspects of gene expression analysis in the PD
brain
Technologies to examine whole genome gene expression have
advanced rapidly in the 15 years since the ﬁrst application of
microarray technology to the analysis of gene expression [71].
The techniques now available include microarray based gene-by-
gene expression, exon microarray analysis and transcriptome RNA
sequencing [4,5,20,60,71,81]. All of these techniques offer genome
wide coverage, with increasing depth of information revealed mov-
ing from simple arrays to exon arrays to sequencing. A detailed
review of the technology underlying these approaches is available
elsewhere in this special issue. The literature describing brain gene
expression studies in the ﬁeld of Parkinson’s disease and related
disorders is summarised in Table 1. Individual studies will be dis-
cussed below, but it is ﬁrst important to consider some of the
general aspects of gene expression studies in the context of a neu-
rodegenerative disease.
There are a series of general strengths and the weaknesses of
the genome wide expression approach. The main strength is an
unprecedented power to look at gene expression across the genome
in a relatively unbiased manner using small amounts of material.
One limitation, highlighted by many authors and common to most
gene expression studies, is that is difﬁcult to separate out cause
and effect. That is, do the changes in gene expression indicate an
underlying cause of the disease, or do they represent a downstream
consequence of the underlying aetiology. While both are of interest
it is important to be able to discriminate between them [91].
Another limitation is that studies such as this are dealing with
a mixed cell population, and a population where one set of sam-
ples has suffered massive cell loss. Because of this, we  need to
consider which brain region(s) we  should examine. Speciﬁcally,
should expression in the Substantia nigra as a whole be assessed
304 P.A. Lewis, M.R. Cookson / Brain Research Bulletin 88 (2012) 302– 312
Table 1
Summary of genome wide gene expression analyses of Parkinson’s disease brain tissue and cells.
Study Year Samples Regions Platform Genes/pathways
highlighted
Notes
Hauser et al. 2003 2 Control SN EST analysis Used serial analysis of gene
expression
Grunblatt et al. 2004 7 PD
7  Control
SN Affymetrix HG
focus, oligo
array
Protein ubiquitination,
SKP1A
Lu  et al. 2005 5 PD SN DA neurons RAP PCR
ﬁngerprinting
Cell survival genes Compared Lewy body +ve
and −ve neurons
Nourredine et al. 2005 3 PD
2  Control
SN Serial analysis
of gene
expression
Following up on GWAS
peaks from previous study
Hauser et al. 2005 6 PD
2  PSP
1  FTDP
5  Control
SN Affymetrix, HG
U133A
Examined overlaps
between disorders
Removal of overlapping
genes allowed hierarchical
segregation of gene
expression phenotypes
between different
neurodegenerative
disorders
Zhang  et al. 2005 15 PD
15 Control
SN, putamen,
Brodmann area 9
Affymetrix, HG
U133A
Ubuiquitin proteasome
system, electron transport
chain
Papapetropolis et al. 2006 22 PD
23 Control
21 brain regions Affymetrix, HG
U133A
MRPS6 (Mitochondrial
ribosomal protein S6)
Lu  et al. 2006 5 Control DA neurons EST analysis Cell survival pathways LCM – compared midbrain
DA neurons to central grey
substance DA neurons
Vogt  et al. 2006 4 PD
4  MS
4  Control
Putamen,
cerebellum,
occipital cortex
Affymetrix, HG
U133A
G protein signalling and
transcriptionalregulation
1 MSA  speciﬁc transcript
dysregulated: FAM49A
Miller et al. 2006 6 PD
8  Control
SN, striatum GE Codelink
20k bioassay
Synaptic genes Principal component
analysis shows segregation
between PD and control
Moran  et al. 2006 15 PD
8 Control
SN Affymetrix, HG
U133A and B
DNAJB1 Same dataset as Moran
et al. [134] and Duke et al.
[135]
Moran  et al. 2007 13 PD
2 PDD
8  Controls
SN Affymetrix, HG
U133
a synuclein, dopamine and
parkin pathways
1 case PDD, 1 case had
concomitant pathological
diagnosis of AD
Grunblatt et al. 2007 13 AD
9 PD
9  Controls
Hippocampus,
cerebellum,
Gyrus frontalis
medialis
Affymetrix, HG
U133A and B
Cannabinoid receptor 2,
Histone, cluster 1 H3e,
nicotinic cholinergic,
receptor a6, bAPP cleaving
enzyme 1
Cantuti-Castelvetri et al. 2007 8 PD
8  Control
SN, DA neurons Affymetrix, HG
X3P
Gender speciﬁc
transcriptional proﬁles,
proteolysis, WNT  pathway,
a  synuclein, PINK1
LCM, 500 DA neurons from
each brain.
Duke  et al. 2007 9 PD
7  Control
SN Affymetrix, HG
U133A and B
Glial speciﬁc genes Compared lateral and
medial SN to identify genes
linked to survival of medial
SN
Langerveld et al. 2007 7 MSA
5  Controls
Rostrol pons Affymetrix, HG
U133A
Mitochondrial function,
ubiquitin, proteasome,
inﬂammation
Stamper et al. 2008 15 PD
13 PDD
14 Control
Posterior
cingulate, cortex
pytamidal,
neurons
Affymetrix HG
U133 + 2.0
mRNA splicing genes LCM of 1000 neurons per
brain
Bossers  et al. 2009 4 PD
4  PDD
8  Control
SN, caudate,
nucleus,
putamen
Custom Agilent
22k arrays
Neurotrophic support and
axon guidance
Hierarchical segregation of
PD vs control in SN but not
other tissues
Simunovic et al. 2009 10 PD
9 Control
SN DA neurons Affymetrix HG
U133A
Mitochondria, ubuiquitin
proteasome system and
programmed cell death
LCM, 300 neurons from
controls, 700 from PD
samples
Elstners et al. 2009 8 PD
9  Control
SN, DA neurons Illumina
WG6v1
MTND2, PDXK, SRGAP3,
TRAPPC4. PDXK, pyroxidal
kinase, linked to increased
risk of PD
LCM, 100 neurons per brain
Zheng et al. 2010 172 PD
139 Control
SN, DA neurons Meta analysis Electron transport chain
genes under the control of
PGC1a
Included LCM data and a
series of subclinical
samples
Simunovic et al. 2010 10 PD
9 Control
SN, DA neurons Affymetrix, HG
U133A
Gender speciﬁc
transcriptional proﬁles
Used same data set as
Simunovic et al. [105]
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y extraction of mRNA from whole brain tissue, or should investi-
ations be focused on speciﬁc neuronal types. The advent of single
ell expression analysis, facilitated by the development of laser cap-
ure microdissection (LCM), has been especially important for the
atter [9,32,95]. Some of the studies discussed below have there-
ore focussed on the surviving dopaminergic nigral cells left at the
ndpoint of disease in the brain [11].
One alternative approach is to examine gene expression outside
f the Substantia nigra. This merits consideration because although
he amount of neuronal cell loss is less dramatic in other area, there
s still Lewy body pathology in a range of brain regions. If we con-
ider PD to be a multi-brain region disease, then there might be
mportant insights from considering where gene expression differ-
nces occur weighting for the contribution to pathology.
A further factor to be taken into consideration when examin-
ng global gene expression in Parkinson’s is the underlying clinical
eterogeneity of the disease, and the emerging realisation that the
oundaries between PD and other neurodegenerative disorders are
ot as distinct as was once thought [94]. Within the diagnosis of
D itself, it is increasingly recognised that a substantial propor-
ion of cases present with a dementia component in addition to
he classical movement disorder phenotype (Parkinson’s disease
ementia or PDD) [1].  Dementia with Lewy bodies (DLB) is an
verlapping disorder where the presenting phenotype is demen-
ia rather than a movement disorder although by the later stages
f disease the distinctions between PD, DLB and PDD are blurred
70,76,86]. In addition, there are the related disorders multiple
ystem atrophy (MSA) and progressive supranuclear palsy (PSP),
hich have substantial clinical overlap with PD but are distinct
linical and pathological entities [109]. Mutations in genes such as
APT also have parkinsonism as part of their clinical presentation
30,56,117].
This is relevant for gene expression studies as a careful appraisal
f clinical and pathological details is required for brain tissue to be
ncluded in studies of PD. The inclusion of disorders with divergent
henotypes and differing pathologies could increase the complex-
ty of data sets that, by their very nature, have a low signal to noise
atio [127]. The heterogeneity and overlap between neurological
isorders should, however, be recognised as an opportunity as well
s a confounding factor, as examining the commonalities between
ene expression alterations in these disorders is potentially illumi-
ating with regard to the disease process in individual disorders
42].
Further to this, a major confounding factor is the underlying
ariation in gene expression due to the different genetic back-
rounds of the samples [113]. Many of the studies performed to data
ave matched cases and controls for known methodological and
iological variables (age, gender and post mortem interval are the
ost commonly considered), but this does not address the poten-
ial for undetected bias in genetic background to introduce either
alse positive or false negative results [21,31,63].
Studies using brain tissue from neurologically normal controls
ave shown there are many common genetic variants in the human
enome that show a statistical association with expression lev-
ls, usually of nearby genes [41]. Perhaps surprisingly, the number
f transcripts where there is an effect of genotype on expression
utweighs the number where age or gender shows an effect. Rel-
tively few studies have attempted to match for genetic variation
nd it would be difﬁcult to do so without having very high num-
ers of samples. However, it is helpful to bear in mind that even the
ost carefully matched sample series are usually quite modest in
umber and are not matched for all known variables.
Following from this, it is important to note which genes can be
eplicated across studies. Genes whose expression differ between
D and controls are often highlighted when they are replicated
cross studies but in practise many more genes are not replicated,rch Bulletin 88 (2012) 302– 312 305
leading to a bias in reporting that hinders critical review. One prob-
lem with attempting to perform meta-analysis of array studies in
particular is that probe designs vary across platforms and are often
not stable even for multiple iterations of the same array product.
Therefore, in the following section we will note where consistency
has been found but will limit comments on lack of replication to
speciﬁc instances where non-array techniques have been used.
In the following sections, we will discuss some of the major
approaches that have been taken in examining PD gene expres-
sion, including homogenised tissue compared to laser captured
individual cells and to material outside the brain.
5. Gene expression in bulk extracts of the Substantia nigra
The ﬁrst description of genome wide expression analysis of PD
brain tissue was published in 2004 by Grunblatt and co-workers
[43]. A case:control approach was  taken to look for differences in
gene expression between brains from seven neurologically normal
individuals and seven PD cases. Whole RNA was extracted from
nigral tissue and gene expression was assessed by whole genome
affymetrix expression arrays.
Analysis of the data from these extracts revealed a large number
of genes up or down regulated between cases and controls (137 in
total), using a threshold of >1.5-fold alteration and deeming a p
value of <0.05 to be signiﬁcant. To decrease the number of genes
under consideration, the authors carried out a second sifting of the
results by limiting the genes studied to those that showed at least a
1.5-fold alteration in 5 out of 6 parkinsonian samples. This limited
the genes to 20, 3 of which were genes down regulated in the PD
brain linked to DA transmission and metabolism, a ﬁnding that was
perhaps to be expected given the widespread DA neuronal loss in
these samples (see above). The same study uncovered a number
of down regulated genes linked to protein degradation, including
the E3 ligase SKP1A. This is of particular interest given the fact that
several genes linked to genetic forms of Parkinson’s disease are
associated with protein degradation [49].
Hauser and co-workers took a different approach, taking advan-
tage of the fact that there are multiple heterogeneous disorders
linked to parkinsonism as a tool to differentiate disease speciﬁc
gene alterations [53]. By extracting mRNA from brain tissue isolated
from patients with PD, PSP and FTDP, along with control samples,
the authors hoped to dissect expression differences speciﬁc to each
disease. The authors were able to identify genes (12 in total) that
displayed altered expression across all three disorders compared
to controls. Based upon the hypothesis that these were more likely
to be linked to generalised neuronal degeneration as a phenotype
secondary to the underlying aetiology, exclusion of these common
genes allowed the hierarchical segregation of the disease groups
– a statistical separation that was  not possible if these genes were
included. Several cellular pathways were identiﬁed as being altered
in the PD samples including those linked to protein misfolding and
degradation, and nuclear encoded mitochondrial genes.
Noureddine and colleagues combined loci identiﬁed by a
genome wide association study that they had previously published
with gene expression data harvested from 3 PD brains and 2 control
samples [69,85,101]. This study focused on a number of genomic
regions identiﬁed in their genome wide association studies as being
linked to age at disease onset and absolute risk for disease, an
approach the authors dub serial analysis of gene expression, fol-
lowing up on an earlier publication examining gene expression in
control Substantia nigra [52]. This is a potentially very powerful
method to dissect the genetic and expression pathways that lead
to neurodegeneration in PD. However both the association study
and the expression study in this case suffer from low sample num-
ber. It is only recently, with the advent of association studies with
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ase control numbers in the thousands, that replicated risk loci
ave been identiﬁed [40]. Using analysis of ESTs, the authors iden-
ify a number of loci within the regions previously identiﬁed by
heir association studies, and note an up regulation of mitochon-
rial encoded genes compared to nuclear encoded mitochondrial
enes in the PD brains compared to controls.
The studies discussed above have examined the expression of
RNA but this only represent a portion of the transcriptome. There
re a small number of studies examining small RNAs in the PD
rain. Kim et al. compared miRNA expression in the Substantia
igra of PD cases and controls and identiﬁed mir-133b as being
ifferentially expressed between cases and controls [62]. They
urther suggested that mir-133b regulates Pitx3, a transcription
actor involved in differentiation of mature dopaminergic neurons,
hus indicating that mir-133b may  have cell-speciﬁc roles. More
ecently, Minones-Moyano and co-workers carried out a study of
1 PD brains compared to 6 pooled control brains looking specif-
cally for miRNAs associated with the disease state, uncovering
iR-34b/c as downregulated in PD samples [79]. The potential role
or miRNAs in PD has recently been reviewed, pulling together
esearch from patient samples and the more extensive literature
rom model systems [50].
. Examining brain regions other than the nigra
Several other studies have compared gene expression in PD tis-
ue to tissue from the brains of people afﬂicted by related, but
eparate, disorders. Vogt et al. compared MSA  to PD and control
issue, with the aim of identifying genes differentially expressed
peciﬁcally in MSA  [124]. They found that GPR86 and RGS14, both
ssociated with G protein signalling, had lower expression in both
SA  and PD putamen. In contrast, Langerveld et al. directly com-
ared gene expression in the rostral pons between 7 MSA  brains and
 control brains [65]. Interestingly, this study identiﬁed changes
ssociated with MSA  in a number of pathways that have also been
mplicated in alterations within the Substantia nigra in PD – notably
own regulated genes linked to the mitochondria and the ubiqui-
in/proteasome system – despite the different anatomical origin
f the tissue and the different pathology associated with these
wo disorders. A number of up regulated genes linked to oligo-
endrocyte maintenance were also identiﬁed, which is potentially
igniﬁcant as one of the major pathological features of MSA  that
s distinct from PD is the presence of -synuclein pathology in
ligodendroglia.
Finally, Grunblatt and colleagues stepped outside Lewy body
isorders altogether to compare brain gene expression between PD
nd AD [44]. The study was primarily focused on AD, and therefore
xamined tissue from the hippocampus, gyrus–frontalis–medius
nd the cerebellum, regions differentially impacted in this disease
26]. They identiﬁed 12 genes that were altered in AD and PD tissue,
long with 4 that displayed differential expression between AD and
D (and control) – suggesting disease speciﬁcity. Intriguingly, one
f these genes was BACE1, which is involved in the proteolytic pro-
essing of the Amyloid Precursor Protein to produce the A peptide,
hich was down regulated in AD and upregulated in PD [123].
Two studies from 2005 and 2006 approached the question of
egional vulnerability in PD by examining differential gene expres-
ion from multiple brain regions. Zhang and colleagues investigated
hree brain regions in 15 PD and 15 control brains [131]. They
dentiﬁed a number of transcripts that were altered across the
ubstantia nigra, putamen and Brodmann area 9, verifying the top
old-changed genes by rtPCR and in situ hybridisation. These three
egions were speciﬁcally chosen as being primarily affected, sec-
ndarily affected and not involved in PD. Statistical and pathway
nterrogation of the results highlighted electron transport chainrch Bulletin 88 (2012) 302– 312
and ubiquitin/proteasome system genes as being differentially
expressed in the tissue most impacted in Parkinson’s disease.
Papapetropolis et al. spread the net a little wider, and studied
a total of 21 different brain regions in 22 PD and 23 control brains
[89]. This group had a slightly different approach, and were specif-
ically looking for genes that were differentially regulated across
the regions examined. However, no genes were altered in the same
way across all 21 brain regions and so the authors lowered the strin-
gency of their search, discovering 11 genes that were regulated in a
similar manner across 18 of 21 brain regions in cases versus control.
They focused on one of these, the mitochondrial ribosomal protein
S6, MRPS6,  a nuclear encoded gene that was  found to be expressed
at higher levels in PD brains compared to controls.
7. Isolating neurons using Laser capture microdissection
Most of the above studies used bulk extractions from tissue to
generate RNA for microarray analyses. As discussed above, a difﬁ-
culty with this approach is that the cellular composition of a brain
where neurodegeneration has been active differs from disease-
free controls. It may  therefore be very helpful to examine speciﬁc
cell types to more directly compare controls and cases and there
are techniques such as Laser capture microdissection (LCM) that
allow for small numbers of cells to be isolated from tissue that
are suitable for array analysis. Additionally, there is a great deal of
information that may  be etiologically relevant to the disease pro-
cess that can be seen in surviving cells. Lewy bodies, an important
clue for pathogenesis, were ﬁrst identiﬁed by histological, and later
by immunological, techniques examining pathology at the cellu-
lar level. Because of these reasons, examining gene expression in
isolated neurons has been attempted by several groups.
Lu et al. used a combination of LCM and PCR ﬁngerprinting to
examine cells from ﬁve PD brains comparing cells containing Lewy
bodies to those without [72]. The role of the Lewy body is PD is
controversial in that it is not clear if the formation of pathological
structures is a toxic event or an attempt by the neuron to respond
to damage and thus represents protection. Equally Lewy bodies
could be both toxic and protective in different contexts or might
be neutral. The analysis of expression by Lu et al. used PCR analysis
of expressed sequence tags (ESTs) to reveal that neurons without
Lewy bodies had signiﬁcantly higher expression of genes linked
to cell survival compared to Lewy body containing neurons. This
suggests that these cells were in better health than their aggre-
gate containing companions and argues against a model where
Lewy bodies act as a protective cellular response to an insult from
aggregated -synuclein [22,116].
Similar to these studies, a number of groups have examined
the subtleties of contrasting gene expression in Parkinson’s dis-
ease dementia (PDD) and PD. Stamper et al. [112] compared gene
expression in cortical neurons isolated by LCM from 14 control
brains, 13 PDD and 15 cognitively normal PD brains, identifying
signiﬁcant differences in gene expression between the two  disease
series. The key pathways they identiﬁed were axonal transport, cell
adhesion and mRNA splicing.
The authors also demonstrated how the same data set could be
used to asked different experimental questions by comparing the
PDD and PD samples. Based on the hypothesis that PDD represents
a natural continuation of PD, and that cognitively normal PD brains
will contain the early markers of degeneration within the cortex
that would have resulted in degeneration and dementia had the
patient survived the disease process for a longer period [2,61].A very different way to examine regional and cellular vulnerabil-
ity was  taken by Lu and colleagues, who  compared gene expression
proﬁles of dopaminergic neurons captured by LCM from the Sub-
stantia nigra (which are devastated in PD) and the central grey
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rea (which is almost completely spared) in control brain samples
73]. Little evidence of differential gene expression was discov-
red between the two populations of DA neurons. The authors also
efer to the fact that, despite similar gene expression proﬁles, the
eurons from these two areas have differing electrophysiological
roperties and connectivity within the brain.
Moran and co-workers carried out a set of experiments based
n the same concept using whole tissue rather than laser-captured
eurons [82,134,135]. This study took advantage of the severe dam-
ge caused to the lateral Substantia nigra in PD compared to the
elative sparing of the medial part of this region [35]. This study
dentiﬁed a large number of genes altered throughout the Substan-
ia nigra, with a number that were speciﬁc to either the lateral
r the medial region. One key ﬁnding was the identiﬁcation of
omocysteine-inducible, ER stress inducible, ubiquitin like domain
ember 1 (HERPUD1) as being up regulated in PD tissue compared
o control. Several other alternatively expressed genes also linked
n to protein folding and degradation pathways, again highlighting
he potential relevance of these pathways to PD.
Several groups have used genome wide expression data from
arkinson’s patient brains to examine the role of gender in the dis-
ase process. Epidemiological studies have shown that gender is a
igniﬁcant risk factor for PD, with men  having a two fold higher
ncidence than women [6,121]. Both Cantuti-Castelvetri et al. and
imunovic et al. examined alterations in gene expression strati-
ed by gender in neurons from the Substantia nigra [15,106]. Both
tudies report gender dependant alterations in gene expression
ithin the Substantia nigra, both in PD and control brain. The for-
er  study highlighted kinase signalling pathways, proteolysis and
NT  pathways as being altered between males and females, as
ell as upregulation of PINK1 and -synuclein in males compared
o females. The latter study, following up on previously published
esearch from the same group, highlighted mitochondrial function
enes as being upregulated in the male brain, suggesting a poten-
ial route to increased incidence in males, although only a small
umber of samples were used for each group [105]. Interestingly,
he Simunovic study attempted to re-analyse the data from the
antuti-Castelvetri paper using different statistical analysis tech-
iques to those originally used and were unable to generate a
ataset that could be used, emphasising the importance of sta-
istical processing in the interrogation of gene expression data
29,83,132].
More recently, Zheng and collaborators – a large consortium of
roups carrying out gene expression studies of PD – carried out a
eta-analysis of existing data on gene expression in PD, along with
 number of new data sets [133]. By combining data from tissue
nd LCM isolated neurons, they were able to include a total of 172
nique PD samples and 139 unique control samples. An interesting
ubset of the data examined in this study consisted of expression
ata from the brains of 16 neurologically normal individuals with
ncidental Lewy body disease, possibly representing a preclinical
tage of disease [3,38].  Carrying out pathway analysis, the authors
ere able to identify 10 gene sets that were consistently and signif-
cantly altered between cases and controls. These included genes
nvolved in the electron transport chain, mitochondrial biogenesis,
lucose utilisation and glucose sensing.
Importantly, genes under the control of the master regulator
GC-1  were under expressed in Parkinson’s tissue and neurons
solated from Parkinson’s Substantia nigra compared to controls.
o test the impact of PGC-1  a series of experiments were car-
ied out in primary rat neurons in culture, examining the impact
f modulating this gene in two experimental models for PD:-
ynuclein and rotenone toxicity. In both systems, PGC-1 was  able
o suppress toxicity, providing experimental evidence to support
he role of this gene in the disease process in PD. In a fascinating
ecent report, PGC-1 has been linked to the process of aging andrch Bulletin 88 (2012) 302– 312 307
telomeric shortening – perhaps providing a unifying theme for the
process of neurodegeneration [97].
8. Gene expression outside of the brain
The brain is not the only tissue type where the association
between disease state and gene expression has been examined. For
example, performing expression analysis in blood has been pro-
posed as a way  to develop novel biomarkers for PD [45,99,103]. Of
interest, Shehadeh et al. have suggested that SRRM2,  a component
of the spliceosome, is differentially spliced comparing PD and con-
trol cases in both brain and blood. This study used exon arrays, a
technique whereby individual exons are interrogated that can give
a semi-quantitative view of alternate splicing in different samples.
Although there are no published results using exon arrays in the
PD brain, this result suggests that looking at splicing in PD versus
controls might be an important line of research in the future, which
will be discussed below.
9. The beneﬁts and drawbacks of genomic expression
analyses in PD
Whole genome approaches have many beneﬁts, particularly the
equal weighting given to large numbers of genes. As noted above,
data can be gathered from multiple brain regions, cell types and
disease pathologies to explore the differences and commonalities
between these samples, expanding our understanding of the under-
lying aetiology of PD.
There are, however, a number of problems when carrying out
or interpreting these studies. One major issue is that of sample
number, a problem that genome wide association studies have bat-
tled with for a number of years [14]. The fundamental problem
is that there is limited power to detect relatively small differ-
ences in the context of the need to correct for large numbers of
multiple tests performed. The ultimate resolution of this issue is
to increase numbers of cases and controls, balanced against the
cost of this effort. For example, successive genome wide associ-
ation studies using increasing numbers of samples have revealed
greater and greater detail of the genetic architecture of this dis-
ease [40,48]. For mRNA measurements, these issues are perhaps
more acute as DNA is largely invariant but mRNA is much more
dynamic in expression levels. These variables make power calcula-
tions in expression studies a fraught topic, even more so than for
association studies [118]. Even with the limited number of sam-
ples analysed across laboratories, meta-analyses can be performed
to improve robustness of results. However, as the raw material for
brain gene expression studies is available only post mortem there
are a large number of quality control problems that are important
to attend to [36,58,126].
Another approach to increasing the signal in such studies is to
focus on genetically deﬁned PD cases. This has become feasible due
to the discovery of increasing numbers of genetic cases in brain
banks and in the patient population. For example, several studies
have recently examined the impact of mutations in LRRK2 on gene
expression in the brain [10,24]. Although potentially informative
with regard to the biology of the speciﬁc gene under consideration,
it is less clear whether such studies will be helpful for understand-
ing alterations in the pathogenesis of sporadic disease.
A central problem speciﬁc to the disease tissue samples, and
one that is difﬁcult to control for is that there are differences in cel-
lular composition between cases and controls. Since the neuronal
loss in the disease impacted areas is extensive, with the majority of
cells having died by the time the patient reaches the end stages of
disease, there are very few remaining cells in the tissue for mRNA
to be extracted from [35,87].  Those cells that remain may have an
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xpression proﬁle that reﬂects a dying cell, rather than the underly-
ng insults that led to disease originally. In most neurodegenerative
onditions there is some reactive astrogliosis and microglial activa-
ion. Sampling subsets of cells using LCM overcomes many of these
ifﬁculties, but it remains ambiguous whether the cells remaining
n an advanced neurodegenerative disease brain are resistant to the
isease process due to their phenotype or altered survival pathway
xpression. Staging of brains may  be helpful in identifying early
athological events, but even then the amount of pathology in early
tage disease may  still be extensive. There are not many practical
olutions to these problems if we wish to study the human dis-
ase although meta-analytic approaches would appear to be a very
romising strategy [133].
An added set of confounding factors that apply as much to
ontrol tissue as to disease samples, are the variations in brain
tate at the point of death and the nature of post mortem han-
ling. One widely used measure of tissue quality is post mortem
nterval, the time between death and freezing of brain tissue. The
amples described in papers referred to throughout this review pos-
ess widely varying post mortem. To cite one example, the study by
u et al. in 2006 had post mortem delays of between 7 and 47 h
73]. Attempts have been made to decrease the length of delay for
rain bank samples, for example by the Sun Health Research Insti-
ute Brain Bank in Phoenix, Arizona [8].  While such efforts are to
e lauded, there is not a simple relationship between length of post
ortem delay and the quality of RNA isolated from brain samples
17,33,51,93]. Whether post mortem delay has an impact on the pat-
ern of gene expression is less clear with some analyses suggesting
hat it may  have a measurable effect [7,37].
Factors that are better predictors of RNA quality are the agonal
tate of the individual, particularly if a person died in a manner
here the brain was relatively anoxic for a period of time. A sur-
ogate measure of agonal state is the pH of the brain post mortem
7,51,80,93], although this is not always used. The majority of the
tudies described in this review use one of a number of quality
ontrol measures to account for degradation of RNA, for example
ssessing RNA integrity number (RIN) developed by Agilent tech-
ology [100]. How well this correlates with the quality of RNA
uality across the transcriptome is not well studied, although a
ecent study suggests that there might not be a direct relation-
hip between the two [119]. In addition, a remaining concern is
hat cause of death in neurologically normal individuals tends to
e different (heart attacks and cancer are common) to PD patients,
nd so agonal state and assignment into cases and controls can be
orrelated, confounding analysis [55].
All of these factors combine to make the analysis of gene expres-
ion in the PD brain a particularly challenging task. However,
ppropriately powered sample series can be constructed with mod-
rate power where age, gender and biological measures of brain
RNA integrity can be reasonably controlled for. Surprisingly, in a
arge series of control brains where we have measured expression,
any of the above parameters (post mortem delay, age and gen-
er) have smaller effects on gene expression than some technical
ariables. There are clear differences in expression between sam-
les from the same brain region submitted from different brain
anks. However, the largest effect, even after robust normalisa-
ion approaches is the effect of batch of hybridisation of the arrays.
his effect is not well studied, and is only apparent in larger series.
ne pragmatic approach to deal with this is to use multivariate
egression to correct for known biological and technical variables.0. The future of gene expression analysis in Parkinson’s
The technologies driving genome wide analysis are advancing
apidly [64,74]. As can be seen from this survey of the existingrch Bulletin 88 (2012) 302– 312
literature, the level of sophistication of gene expression studies in
the PD brain has increased signiﬁcantly even over the last 10 years.
However, there are a number of newer technologies that have yet
to be applied to this problem.
To date, published analyses of PD brains have used gene-by-
gene expression arrays but there are newer techniques that apply
array technology to events such as alternative splicing [75,88].  The
importance of taking splicing into consideration in the context
of neurological disease is highlighted by the presence of splicing
mutations in the MAPT gene, leading to dementia and parkinson-
ism [56]. Variation at the MAPT locus has been identiﬁed as a risk
factor for sporadic PD [104]. Measuring splicing with arrays has
been used both for analysing brain tissue and in a disease setting
[20,130]. One study using exon arrays has been carried out on blood
isolated from PD patients and controls [103].
A very recently developed technology is deep sequencing, which
can be applied to RNA quantiﬁcation, called RNAseq [122]. The
advantages of RNAseq over microarray-based measurements are
that it is theoretically feasible to measure both expression levels
and modiﬁcations such as splicing and RNA editing. There is some
evidence that RNAseq data has a better dynamic range than arrays,
and therefore is more predictive of true levels of gene expres-
sion, especially for lower abundance transcripts [125]. In principle,
because RNAseq is a library based approach rather than based on
designed oligonucleotide probes, there is also the possibility of dis-
covery of novel transcripts. In the next several years, it is likely
that there will be increasing use of RNAseq on samples from PD
patients, as the cost of this technology decreases and it becomes
more widely available. The issues regarding samples from diseased
brains raised above will, however, apply equally to RNA sequenc-
ing as to microarray analysis, and so the challenge of working with
PD brain samples will be just as large as for the lower resolution
techniques. For high cost techniques, there is a tendency to pool
samples or to use sample series of limited power, which is likely to
be the major confound of early studies.
An alternative approach, which was touched upon by Noured-
dine and co-workers, combines data from genome wide association
studies with gene expression data [85]. As the data from the current
batch of large scale PD genome wide association studies becomes
available, this is an approach that may  yield a huge amount of useful
information, as it does not necessarily rely upon the use of dis-
eased tissue, instead examining gene expression in normal tissue
of the genotype under investigation [23,40]. A cautionary note on
this subject is that the size of effect of individual loci on lifetime
risk for PD are modest at best, and it is likely that any alterations
in gene expression that ensue from these genetic variations may
also be modest. However, we have shown previously that there is
evidence of similar expression quantitative trait loci for some, but
not all, small effect loci.
A technique that offers another angle of approach to the issue
of gene expression in PD is live cell analysis. Advances in the ﬁeld
of stem cell biology have opened the possibility of using neuronal
cells derived from embryonic stem cells to model degeneration
in an ex vivo environment [47]. This approach removes a number
of the technical issues that plague analysis of mRNA from brain,
while introducing a number of unknown quantities – for example
it is not yet apparent how closely neuronal populations generated
ex vivo match neuronal cells in an in vivo setting. With speciﬁc
regard to PD, the application of induced pluripotent stem cell tech-
nology to sporadic and inherited forms of PD yields the potential
to generate patient speciﬁc neuronal populations, which can then
be used to examine gene expression [25,108,115]. Much remains
to be discovered about how well human embryonic and induced
pluripotent cells model the human condition, but this is a tech-
nique that may  prove useful for future analyses of gene expression
in PD.
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fig. 1. From brain tissue to genomic analysis. The ﬂow of information from brain
amples through the puriﬁcation process and the different systems that can be used
o  analyse gene expression.
Finally, there are increasing opportunities to combine mRNA
nalyses with genome wide DNA sequence data and whole genome
pigenetic mapping [34,54].  Again, this is perhaps best performed
y examining gene expression at risk loci for a disease in control
rains. We  have shown that there are several risk loci for PD that
re associated with differences in CpG methylation, particularly at
he HLA locus on chromosome 6 [84]. The potential alternatives
ith regard to genomic analysis of a given sample of Parkinson’s
rain tissue are summarised in Fig. 1.
1. Good practices for gene expression studies in PD brain
Like all experiments, array studies require consideration of how
o design and perform the experiments to yield interpretable data.
he key recommendation, which has been made for other types of
icroarray studies, is that the power of a series to detect changes
f a given magnitude should be considered when designing experi-
ents. Given the need to correct for multiple testing, sample series
ight need to be relatively large to detect small differences and
eta-analyses may  be helpful. For this, deposition of raw data in
ublic resources is encouraged.
Experimental variables should be controlled where possible,
lthough for human post mortem studies there are practical con-
traints on ideal design. However, recognition that, statistically,
ome parameters are more important than other may  help priori-
ize which aspects are more important. In an ideal design, samples
rom PD and controls would be ascertained from the same centre
nd would be hybridised in as few batches as possible, randomising
ases and controls. Other known co-variates such as post mortem
nterval age and gender can be either matched and/or corrected for
n the gene expression model used, but may  have less inﬂuence
n outcome of the experiment. However, RNA quality should be
ssessed, either by measuring brain pH or RIN, and it is helpful to
nly use the highest quality samples available.
Whether examining the nigra or other brain regions is most
ppropriate really depends on the question being asked. If the aim
f the experiment is to examine the most heavily affected cells in
D then nigra is likely the best place to look and, in this context, LCM
r other methods for isolating single cells is an extremely helpful
echnique. If the aim is to look more globally at the brain, then it
s helpful to consider the proposed spread of pathology and have
linical data to hand that might reﬂect the involvement of different
rain regions.
2. ConclusionsThe application of techniques utilising a genomic approach to
uman biology and disease offer much promise in terms of opening
 window on the processes underlying normal cellular and tissue
unction, and how these processes go awry in disease. Genome widerch Bulletin 88 (2012) 302– 312 309
association studies have now demonstrated the utility of these
approaches for PD, and a logical next step for these studies is their
extension into the realm of gene expression. As gene expression
studies of the brain in PD increase in size and complexity, it is
likely that they will start to show the return that is already apparent
for the association studies. When this is coupled to the increasing
sensitivity and decreasing cost of genomic, transcriptomic and pro-
teomic technologies, it is likely that the next few years will be an
exciting time for the analysis of gene expression in PD.
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